Beyond Air Schedules First Fiscal Quarter 2024 Financial Results Conference Call and Webcast

Call scheduled for Thursday, August 10ᵗʰ at 4:30 pm Eastern Time

GARDEN CITY, N.Y., July 24, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its affiliate Beyond Cancer, Ltd.), today announced that it will report financial results for its first fiscal quarter ended June 30, 2023 on Thursday, August 10, 2023. The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.

Conference Call & Webcast
Thursday, August 10th @ 4:30 PM ET
Domestic:	1-888-999-6281
International:	1-848-280-6550
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1626173&tp_key=e8a224 ...

About Beyond Air, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors. The Company has received FDA approval for its first system, LungFit PH for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other LungFit systems in clinical trials for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM). The Company has also partnered with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of Autism Spectrum disorder (ADS) and other neurological disorders. Beyond Cancer, Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more information, visit www.beyondair.net.